Yan Wu

US Patent:

20220235104, Jul 28, 2022

Filed:

Jul 3, 2019

Appl. No.:

17/257951

Inventors:

- Oakland CA, US
Yan Wu - La Jolla CA, US
Amir Dailamy - La Jolla CA, US
Prashant Mali - La Jolla CA, US
Daniella McDonald - La Jolla CA, US
Udit Parekh - La Jolla CA, US
Michael Hu - La Jolla CA, US

International Classification:

C07K 14/47
A61K 31/522
A61K 45/06
C12N 15/86
C12N 5/071
C12N 15/11
C12N 9/22

Abstract:

This disclosure relates to methods, polynucleotides, vectors, viral particles, cells, and systems or the engineering of human tissues. One aspect of the disclosure relates to using lineage-specific miRNA binding molecules to bias tissue lineage. Another aspect of the disclosure relates to using lineage-specific transcription factor overexpression to bias tissue lineage.

US Patent:

20230082291, Mar 16, 2023

Filed:

Nov 10, 2022

Appl. No.:

17/985044

Inventors:

- West Hills CA, US
Yan Wu - Valley Village CA, US

Assignee:

PHARMAVITE LLC - West Hills CA

International Classification:

A23G 3/42
A23G 3/50

Abstract:

A gummy composition including a gelatin; a pectin; a food-grade organic acid; and water, wherein the gummy composition has a pH of 3.1 to 3.45 or a Brix range of 76 to 81, and wherein the gummy composition has a removal time of 30 minutes or less in a starchless mold. A method of manufacture of a gummy composition comprising at least one of a pH of 3.1 to 3.45 and a Brix range of 76 to 81, and having a removal time of 30 minutes or less in a starchless mold, the method including forming a flowable composition of a gelation, a pectin, a food-grade organic acid and water; and depositing the flowable composition into a starchless mold.

US Patent:

20210345639, Nov 11, 2021

Filed:

May 8, 2020

Appl. No.:

16/870862

Inventors:

- West Hills CA, US
Yan Wu - Valley Village CA, US

Assignee:

PHARMAVITE LLC - West Hills CA

International Classification:

A23G 3/42
A23G 3/50

Abstract:

A gummy composition including a gelatin; a pectin; a food-grade organic acid; and water, wherein the gummy composition has a pH of 3.1 to 3.45 or a Brix range of 76 to 81, and wherein the gummy composition has a removal time of 30 minutes or less in a starchless mold. A method of manufacture of a gummy composition comprising at least one of a pH of 3.1 to 3.45 and a Brix range of 76 to 81, and having a removal time of 30 minutes or less in a starchless mold, the method including forming a flowable composition of a gelation, a pectin, a food-grade organic acid and water; and depositing the flowable composition into a starchless mold.

US Patent:

20210108193, Apr 15, 2021

Filed:

Sep 22, 2020

Appl. No.:

17/028836

Inventors:

- Oakland CA, US
Udit Parekh - La Jolla CA, US
Yan Wu - La Jolla CA, US
Kun Zhang - La Jolla CA, US

International Classification:

C12N 15/10
C12N 5/071
C12N 15/86
A61K 35/44

Abstract:

Understanding the complex effects of genetic perturbations on cellular state and fitness in human pluripotent stem cells (hPSCs) has been challenging using traditional pooled screening techniques which typically rely on unidimensional phenotypic readouts. Here, Applicants use barcoded open reading frame (ORF) overexpression libraries with a coupled single-cell RNA sequencing (scRNA-seq) and fitness screening approach, a technique we call SEUSS (ScalablE fUnctional Screening by Sequencing), to establish a comprehensive assaying platform. Using this system, Applicants perturbed hPSCs with a library of developmentally critical transcription factors (TFs), and assayed the impact of TF overexpression on fitness and transcriptomic cell state across multiple media conditions. Applicants further leveraged the versatility of the ORF library approach to systematically assay mutant gene libraries and also whole gene families. From the transcriptomic responses, Applicants built genetic co-perturbation networks to identify key altered gene modules. Strikingly, we found that KLF4 and SNAI2 have opposing effects on the pluripotency gene module, highlighting the power of this method to characterize the effects of genetic perturbations. From the fitness responses, Applicants identified ETV2 as a driver of reprogramming towards an endothelial-like state.

US Patent:

20190330661, Oct 31, 2019

Filed:

Jun 28, 2017

Appl. No.:

16/312907

Inventors:

- Oakland CA, US
Prashant MALI - La Jolla CA, US
Yan WU - La Jolla CA, US
Dongxin ZHAO - La Jolla CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12N 15/90
C12N 15/10
C12N 9/22
G16B 20/20
G16B 25/10
G16B 40/10
C12N 15/113

Abstract:

A guide RNA comprising: a gRNA spacer sequence at the 5′ end of the guide RNA, wherein the spacer sequence is complementary to a target gene, a scaffold sequence that binds to Cas9, and an RNA capture and sequencing domain comprising: a barcode sequence, and a primer binding sequence; nucleic acids and vectors encoding the guide RNA; cells expressing the guide RNA; and a library comprising a plurality of guide RNAs. Also disclosed are methods of introducing a genetic perturbation into a cell, methods of assessing an effect of at least one genetic perturbation on RNA expression in a cell, methods of identifying nucleic acid sequences associated with a disease state and a method of identifying candidate therapeutic agents.